Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Gynecol Oncol. 2015 Jul 15;138(3):507–512. doi: 10.1016/j.ygyno.2015.07.018

Figure 1. Progression-free survival (PFS) and overall survival (OS) of endometrial cancer patients receiving single agent cediranib.

Figure 1

Kaplan-Meier plot of progression-free survival (solid line) and overall survival (dashed line). The median PFS was 3.65 (90% CI 2.37 ~ 5.49). The median OS was 12.5 (90% CI 7.0 ~ 14.5).